^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    m-ceNK cells

    i
    Other names: m-ceNK cells, memory cytokine-enriched natural killer cells
    Associations

    News

    Trials
    Company:
    ImmunityBio
    Drug class:
    NK cell stimulant, IFNγ stimulant
    Related drugs:
    Associations

    News

    Trials
    18d
    A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer (clinicaltrials.gov)
    P2, N=20, Recruiting, ImmunityBio, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    gemcitabine • Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
    23d
    A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, ImmunityBio, Inc.
    New P2 trial • Combination therapy
    |
    gemcitabine • Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
    2ms
    QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=50, Recruiting, ImmunityBio, Inc. | Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    CD4 (CD4 Molecule) • NKG2D (killer cell lectin like receptor K1)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
    over1year
    QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=50, Recruiting, ImmunityBio, Inc. | N=30 --> 50 | Trial completion date: Jun 2022 --> Dec 2024 | Trial primary completion date: Jun 2022 --> Jun 2024
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
    over3years
    QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=30, Recruiting, ImmunityBio, Inc. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
    over3years
    QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, ImmunityBio, Inc.
    Clinical • New P1 trial
    |
    CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells